LONDON , July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc ...
President Donald Trump’s stock transaction filings reveal multiple purchases of Moderna ($MRNA) during March 2026, followed by a partial sale on May 18. Since those trades, the FDA's Vaccines and Related...
Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.
/Solventum%20Corp-%20healthcare%20phone-by%20ipopba%20via%20iStock.jpg)
Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?
First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment 1 ...
First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs...
Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc ...